Anti-her2 vaccine based upon aav derived multimeric structures
WO2012031760A1
Parvovirus mutated structural proteins comprising cross - protective b - cell epitopes of a hpv l2 protein as well as products and methods relating thereto
EP2394640A1
Improved liposomal formulations of lipophilic compounds
US2010034796A1
Inhibitors of fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction
WO2009121629A1
Solubilisation method
HUE036490T2
Treatment of tumors using specific anti-L1 antibody
EP2158211A2
Mutated structural protein of a parvovirus
EP2086508A2
Cationic colloidal carriers for delivery of active agents to the blood-brain barrier in the course of neuroinflammatory diseases
WO2008043576A1
Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
WO2008006535A2
Use of a cationic colloidal preparation for the diagnosis and treatment of ocular diseases
EP2012122A1
Mutated parvovirus structural proteins as vaccines
EP2040674A1
Cationic liposomal preparations for the treatment of rheumatoid arthritis
BRPI0709075A2
negative receptor triple breast cancer treatment
WO2007082726A2
Flowable leuprolide-containing composition for treating inflammation-mediated neurodegenerative diseases
EP1920765A1
Liposome preparation by single-pass process
EP1915987A1
Spray-freeze-drying process for the preparation of pellets comprising percolation drying
US2005249745A1
Papilloma virus truncated L1 protein and fusion protein constructs
MXPA06003404A
The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin.
WO2004101800A1
Dna constructs and vectors for the inducible expression of nucleotide sequences
